ERBB2 and triple-negative breast carcinoma: In particular, patients with specific breast cancer subtypes, namely triple negative breast cancer (TNBC) or hormone receptor negative/human epidermal growth factor receptor (HER2) positive cancers, can achieve complete pathological response (pCR) approaching 70 per cent in the breast and axilla.